WHo IS SEVENTH SENSE?

Seventh Sense Biosystems has designed and developed TAP™, the world’s first push-button blood collection device. It makes the process simple, convenient, and virtually painless. $50 billion is spent annually on diagnostics and consumers are demanding more from the healthcare system. The company aims to create a new standard for blood collection that increases patient compliance with testing orders, leading to faster diagnoses and better outcomes. Future versions of TAP will enable patients to collect their own blood anywhere. 

Investors

MANAGEMENT TEAM

Howard J. Weisman - Chief Executive Officer and President
Bio

Mr. Weisman is an accomplished entrepreneur in the life sciences industry. Prior to joining Seventh Sense, he was the founder, chairman, and CEO of EKR Therapeutics, a specialty pharmaceutical company focused on the hospital critical care market. He also co-founded ESP Pharma, where he served as a director as well as the company’s president and chief operating officer until its sale to PDL Biopharma in 2005. Mr. Weisman began his career in sales and marketing at Merck & Co., later moving to Parke-Davis where he launched that company’s diabetes franchise in 1997. He graduated with a BA in chemistry from Rutgers University.

Tim Richards - Chief Operating Officer
Bio

Mr. Richards joined Seventh Sense Biosystems in 2013, bringing a diverse set of international experience and expertise in general management, operations, commercial management, and strategy in the medical device field. Prior to Seventh Sense, Mr. Richards was president of Facet Technologies, a supplier to major diagnostic companies. Previous experience includes executive-level positions at Covidien, where he was president of US patient care and safety, and president of VNUS, a $440 million acquisition. He was also the chief marketing officer at B. Braun Medical, and held a number of commercial and strategic leadership positions with Becton Dickinson & Company in the US and Asia.

Mr. Richards received his BA from Lake Forest College and has participated in executive management and organizational development programs at Stanford Business School, the European School of Management and Technology, and American University.

Stuart Blitz - Chief Business Officer
Bio

Mr. Blitz brings a proven history of building medical device companies from an early stage. Prior to Seventh Sense, he was the first employee at AgaMatrix, a blood glucose monitoring company that made the world’s first medical device connecting directly to the iPhone. He helped grow the company from a startup to one with over 15 FDA-cleared products and 750 employees, forging partnerships with Apple, Sanofi, CVS, and Target. Stuart holds a B.S. in Biomedical Engineering from The Johns Hopkins University and an M.S. in Investment Management from Boston University.

Milan Kofol - Chief Financial Officer
Bio

Mr. Kofol is an experienced financial executive in the medical device and pharmaceutical industries. Mr. Kofol served as Vice President Treasurer and Investor Relations at Boston Scientific Corporation. Prior financial experience includes audit, domestic and international controllership and treasury positions at Wyeth Pharmaceuticals. Mr. Kofol received his BA degree from Presbyterian College and MBA from Wharton School. He also holds CPA certification.

Jerry Brightbill - Vice President of Engineering and Manufacturing Operations
Bio

Mr. Brightbill is an accomplished medical product development and commercialization engineer with more than 25 years of experience developing and marketing a wide variety of disposable medical and catheter-based vascular devices. He came to Seventh Sense from Vention Medical where he was the Program Manager. Prior to that, he was director of catheter research and development at Infraredx, Inc. where he designed, prototyped, tested, and commercialized near-infrared spectroscopy catheters to detect vulnerable plaque in coronary arteries.

Mr. Brightbill also worked for Medtronic AVE as an engineering manager and global marketing product manager, playing a key role in product acquisition and technology transfers. He has a BS in mechanical engineering from Bucknell University and an MBA from Northeastern University.

BOARD OF DIRECTORS

Alan Crane - General Partner, Polaris Partners
Bio

Alan Crane joined Polaris Partners in 2002 and serves as both a Partner and Entrepreneur focusing on building and investing in healthcare companies. He has served as founder and/or has played a significant role as chairman and CEO in building six Polaris companies including: Momenta Pharmaceuticals (NASDAQ: MNTA), Cerulean Pharma (NASDAQ:CERU), Visterra,Navitor Pharmaceuticals, XTuit Pharmaceuticals and Arsia Therapeutics (acquired by Eagle Pharmaceuticals). In addition, he currently serves on the board of Seventh Sense Biosystems and has previously represented Polaris on the boards of T2 Biosystems (NASDAQ: TTOO), Ocular Therapeutix (NASDAQ: OCUL), Sirtris Pharmaceuticals (NASDAQ: SIRT, acquired by Glaxo SmithKline) and Adnexus Therapeutics (acquired by Bristol Myers Squibb).

From 2002 to 2006, Alan was President and CEO of Momenta Pharmaceuticals (NASDAQ: MNTA). He joined Momenta as the fifth employee and built it into a public company, creating an advanced and diversified pipeline, entering into two strategic collaborations with Novartis and raising $275 million. The first product from Momenta’s pipeline achieved over $1B during its first year of sales.

Prior to Polaris, Alan was Senior Vice President of Global Corporate Development at Millennium Pharmaceuticals, where he was responsible for leading Millennium’s strategic partnering, mergers and acquisitions, and licensing activities, generating over $2B in partner funding and acquiring 19 development stage products. Among these products was Velcade® which became the main basis of the company’s $9B acquisition by Takeda. Before joining Millennium, Alan was a marketing executive at DuPont-Merck and a consultant with the Boston Consulting Group and Arthur D. Little.

Alan received the Ernst & Young’s Entrepreneur of the Year award for New England and is an Always-On Venture Capital 100 recipient. His current and former non-profit positions include: Selection Committee for the Harvard Life Lab,expert-in-residence at the Harvard School of Engineering, Board Member of the Boston Children’s Hospital Trust, founder and vice chair of the Autism Consortium, and President of the Board of Gann Academy.

Alan earned a BA in Biology, summa cum laude, from Harvard College, an MA in Cellular and Developmental Biology from Harvard Graduate School of Arts & Sciences and an MBA, with honors, from Harvard Business School. He also spent two years studying towards an MD at Harvard Medical School.

Alan enjoys spending his free time traveling with his wife and three sons and working with non-profits in education and healthcare.

Harry Wilcox - Chief Operating Officer and General Partner, Flagship Pioneering
Bio

Mr. Wilcox joined Flagship Pioneering in 2006, bringing a rich set of experiences and expertise in financial management, operations, fund management and strategy. He oversees the firm’s financial operations and LP relations/fundraising, and serves as board member or advisor to select portfolio companies. Most recently, he served as CFO and senior vice president of corporate development for EXACT Sciences, one of Flagship’s portfolio companies. Mr. Wilcox is currently a board member of Black Duck, Celexion, Seahorse Bioscience, T2 Biosystems and Tangent Medical. He earned a BS in finance from the University of Arizona and an MBA from Boston University School of Management.

Robert Langer, SCD - (Co-founder) Institute Professor, MIT
Bio

Dr. Langer is one of 14 Institute professors at MIT. He has done pioneering work in the areas of biomaterials, drug delivery, and bioengineering, most recently applying nanotechnology to the development of novel diagnostics and therapeutics. Dr. Langer has written more than 1,000 articles and has more than 700 issued or pending patents. His patents have been licensed or sublicensed to more than 180 pharmaceutical, chemical, biotechnology and medical device companies.

Dr. Langer founded more than 20 successful companies, including Momenta Pharmaceuticals, Advanced Inhalation Research (AIR), Transform Pharmaceuticals, T2 Biosystems, BIND Biosciences, and Selecta Biosciences. He is one of very few people ever elected to all three US National Academies and the youngest (at age 43) to receive this distinction. In July 2007, he was awarded the National Medal of Science, the highest civilian honor the country bestows. Dr. Langer received his BS from Cornell University and his ScD from the Massachusetts Institute of Technology, both in chemical engineering.

Howard J. Weisman - Chief Executive Officer and President
Bio

Mr. Weisman is an accomplished entrepreneur in the life sciences industry. Prior to joining Seventh Sense, he was the founder, chairman, and CEO of EKR Therapeutics, a specialty pharmaceutical company focused on the hospital critical care market. He also co-founded ESP Pharma, where he served as a director as well as the company’s president and chief operating officer until its sale to PDL Biopharma in 2005. Mr. Weisman began his career in sales and marketing at Merck & Co., later moving to Parke-Davis where he launched that company’s diabetes franchise in 1997. He graduated with a BA in chemistry from Rutgers University.

Peter Hutt, JD - Senior Counsel, Covington & Burling, LLP
Bio

Mr. Hutt is a senior counsel in the Washington, DC law firm of Covington & Burling, where he specializes in food and drug law. Mr. Hutt served as chief counsel for the Food and Drug Administration between 1971-1975. He is the co-author of the casebook used to teach food and drug law throughout the country, and teaches a course on the subject at Harvard Law School.

Mr. Hutt has been a member of the Institute of Medicine since it was founded in 1971. He serves on government, academic, and venture capital advisory boards, and on the boards of numerous startup biotechnology companies. Washingtonian Magazine named him one of Washington’s 50 best lawyers (out of more than 40,000), and one of Washington’s 100 most influential people. The National Law Journal honored him as one of the 40 best healthcare lawyers in the United States, while the European Counsel named him the best FDA regulatory specialist in Washington.

Marc Ceulemans - Head Strategic Venture Capital & Pharma Equities
Bio

Marc Ceulemans serves as the Head Strategic Venture Capital Fund – Pharma Equities at Novartis Pharma. In addition, Marc supports the NVF on a variety of issues. Before this appointment he held the position of Head of Finance, Global Business Development & Licensing (Novartis Pharma). Prior to joining Novartis Marc was CFO Europe at Johnson Controls and spent several years at Johnson & Johnson in various countries/roles. Marc holds an MBA from Université Libre de Bruxelles (Solvay Business School), a MA in Economics (Lessius Hogeschool Antwerp) and a MA in Financial Management (Vlaamse Economische Hogeschool-Brussels) and Bs.Natural Sciences (Open University, still in process).

Don Hardison - Former President & CEO of Good Start Genetics
Bio

Mr. Hardison joined the Board in 2016. He brings a broad private and public company background in both emerging and Fortune 500 companies. Most recently he was the President, CEO and Director of Good Start Genetics, Inc., a leading molecular diagnostics and information company, specializing in genetic screening for inherited disorders utilizing a proprietary next-generation sequencing platform. Prior to joining Good Start Genetics, he was an Executive Vice President & Chief Operating Officer at Laboratory Corporation of America Holdings (NYSE: LH) in Burlington, North Carolina. Don has served as President, CEO and Director of EXACT Sciences Corporation (NASDAQ: EXAS), an applied genomics/biotechnology company focused on the early detection of cancer. Over the past 30 years, he also has worked as a Managing Partner of OnTarget, a sales and marketing consulting firm, and has held numerous leadership roles at Quest Diagnostics and SmithKline Beecham Corporation. He holds a bachelor’s degree from the University of North Carolina, Chapel Hill.

Scientific Advisors

R. Rox Anderson, MD - (Co-founder) Massachusetts General Hospital and Harvard Medical School
Bio

Dr. Anderson is professor at Harvard Medical School, an adjunct professor at MIT, and directs the Wellman Center for Photomedicine at Massachusetts General Hospital in Boston, the world’s largest academic facility dedicated to the use of light for diagnosis and therapy. He conceived and developed the use of selectively absorbed laser pulses, which are now the primary procedure used to treat birthmarks, pigmented lesions, tattoos, hypertrichosis, and other conditions.

Active research includes diagnostic tissue imaging and spectroscopy, photodynamic therapy, mechanisms of laser-tissue interactions, and novel therapy for skin disorders. Dr. Anderson received his undergraduate degree from MIT and his MD from Harvard Medical School through the MIT-Harvard Health Sciences and Technology program.

Howard Bernstein, MD, Phd, MD - Chief Scientific Officer, SQZ Biotech
Bio

Dr. Bernstein has more than 25 years of experience in technology and drug development. He was involved in the development of eight products during his career, including Nutropin Depot, the first FDA-approved sustained release drug. Before joining Seventh Sense, Dr. Bernstein was executive vice president of research and development at Acusphere, Inc. He previously served as vice president of pharmaceutical development at Alkermes.

He is a member of the National Academy of Engineering and holds 250 patents and patent applications. Dr. Bernstein received his PhD in chemical engineering from MIT and his MD from Harvard Medical School via the MIT-Harvard Health Sciences and Technology program.

Joerg Lahann, PhD (Co-founder) – Dow Corning Associate Professor of Chemical Engineering, University of Michigan
Bio

Dr. Lahann’s research explores the scientific interface between materials chemistry and biotechnology. His work resulted in key materials technologies including reversibly switching surfaces, anisotropic nanocolloids, and multifunctional nanocoatings. Technology Review named Dr. Lahann one of the top young innovators.

He is also the recipient of the 2007 AICHE Nanoscale Science and Engineering Award, a National Science Foundation CAREER award, and a Department of Defense Idea award. Dr. Lahann has published more than 70 papers and contributed to more than 20 patents and patent applications. He received his MS and PhD in macromolecular chemistry from RWTH Aachen.

Robert Langer, SCD - (Co-founder) Institute Professor, MIT
Bio

Dr. Langer is one of 14 Institute professors at MIT. He has done pioneering work in the areas of biomaterials, drug delivery, and bioengineering, most recently applying nanotechnology to the development of novel diagnostics and therapeutics. Dr. Langer has written more than 1,000 articles and has more than 700 issued or pending patents. His patents have been licensed or sublicensed to more than 180 pharmaceutical, chemical, biotechnology and medical device companies.

Dr. Langer founded more than 20 successful companies, including Momenta Pharmaceuticals, Advanced Inhalation Research (AIR), Transform Pharmaceuticals, T2 Biosystems, BIND Biosciences, and Selecta Biosciences. He is one of very few people ever elected to all three US National Academies and the youngest (at age 43) to receive this distinction. In July 2007, he was awarded the National Medal of Science, the highest civilian honor the country bestows. Dr. Langer received his BS from Cornell University and his ScD from the Massachusetts Institute of Technology, both in chemical engineering.

Samir Mitragotri, PhD (Co-founder) – Professor of Chemical Engineering,
University of California, Santa Barbara
Bio

Dr. Mitragotri, whose research interests lie in novel methods of drug delivery, has published more than 80 peer-reviewed journal articles, edits several journals in the field of drug delivery, and is a co-inventor in more than 30 issued and pending patents. He has received numerous awards for his work, including the Technology Review Young Innovator award, and distinctions from the Controlled Release Society, the American Pharmaceutical Association, and the American Institute of Chemical Engineers. Dr. Mitragotri received his MS and PhD in chemical engineering from MIT.

Shannon Stott, PhD - Assistant Geneticist, Massachusetts General Hospital
Cancer Center; Assistant Professor, Department of Medicine, Harvard Medical School
Bio

Professor Stott is a Mechanical Engineer that has been working at the interface of technology, imaging and medicine. She has an extensive background in microfluidics, optics, tissue engineering, biopreservation, with a focus on their applications in clinical medicine and cell biology. As a postdoctoral fellow in Mehmet Toner’s laboratory, she co-invented the herringbone circulating tumor cell chip (HBCTC-Chip) a device that can successfully capture cancer cells circulating in the blood stream cancer patients. The Stott laboratory is now focused on developing microfluidic technologies that can isolate tumor-specific extracellular vesicles from cancer patient blood. Dr. Stott is a pioneer in the field of high speed video microscopy, an imaging technique that has enabled the exploration of novel fluidic flow inside microfluidic devices. In 2014, Dr. Stott received the American Cancer Society’s Women Leading the Way to Wellness Award.

David Walt, PhD - Robinson Professor of Chemistry,
Howard Hughes Medical Institute Professor, Tufts University
Bio

Dr. Walt is a member of the National Academy of Engineering, has published more than 200 peer-reviewed journal articles, and has more than 50 issued and pending patents. He is also a founding scientist, director, and chairman of the scientific advisory boards for Illumina, Inc., and Quanterix Corporation. His current research focuses on applying micro- and nanotechnology to problems such as the analysis of genetic variation and the behavior of single cells, as well as the practical application of arrays to the detection of explosives, chemical warfare agents, and food and waterborne pathogens. Dr. Walt received his BS in chemistry from the University of Michigan and his PhD in chemical biology from SUNY at Stony Brook.